298 related articles for article (PubMed ID: 22241281)
1. No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol: a double-blind placebo-controlled trial.
Park CH; Park TW; Yang JC; Lee KH; Huang GB; Tong Z; Park MS; Chung YC
Int Clin Psychopharmacol; 2012 Mar; 27(2):114-20. PubMed ID: 22241281
[TBL] [Abstract][Full Text] [Related]
2. Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol.
Chung YC; Park TW; Yang JC; Huang GB; Zhao T; Oh KY; Kim MG
J Clin Psychopharmacol; 2012 Dec; 32(6):778-86. PubMed ID: 23131890
[TBL] [Abstract][Full Text] [Related]
3. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
[TBL] [Abstract][Full Text] [Related]
4. Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial.
Mas S; Gassó P; Fernández de Bobadilla R; Arnaiz JA; Bernardo M; Lafuente A
Hum Psychopharmacol; 2013 Nov; 28(6):586-93. PubMed ID: 24519692
[TBL] [Abstract][Full Text] [Related]
5. Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers.
Veselinović T; Schorn H; Vernaleken I; Schiffl K; Hiemke C; Zernig G; Gur R; Gründer G
Psychopharmacology (Berl); 2011 Dec; 218(4):733-48. PubMed ID: 21643673
[TBL] [Abstract][Full Text] [Related]
6. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
Janicak PG; Glick ID; Marder SR; Crandall DT; McQuade RD; Marcus RN; Eudicone JM; Assunção-Talbott S
J Clin Psychiatry; 2009 Jan; 70(1):25-35. PubMed ID: 19192472
[TBL] [Abstract][Full Text] [Related]
7. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
8. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
Chen CK; Huang YS; Ree SC; Hsiao CC
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1495-9. PubMed ID: 20732372
[TBL] [Abstract][Full Text] [Related]
9. Intramuscular aripiprazole in the control of agitation.
Currier GW; Citrome LL; Zimbroff DL; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
J Psychiatr Pract; 2007 May; 13(3):159-69. PubMed ID: 17522559
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole: new drug. Just another neuroleptic.
Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
[TBL] [Abstract][Full Text] [Related]
11. Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study.
Kim SW; Shin IS; Kim JM; Yang SJ; Hwang MY; Yoon JS
J Clin Psychopharmacol; 2008 Jun; 28(3):349-52. PubMed ID: 18480697
[No Abstract] [Full Text] [Related]
12. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
13. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study.
Andrezina R; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; McQuade RD
Curr Med Res Opin; 2006 Nov; 22(11):2209-19. PubMed ID: 17076982
[TBL] [Abstract][Full Text] [Related]
14. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
Andrezina R; Josiassen RC; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; Iwamoto T
Psychopharmacology (Berl); 2006 Oct; 188(3):281-92. PubMed ID: 16953381
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
Daniel DG; Currier GW; Zimbroff DL; Allen MH; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
J Psychiatr Pract; 2007 May; 13(3):170-7. PubMed ID: 17522560
[TBL] [Abstract][Full Text] [Related]
16. Severe psychotic exacerbation during combined treatment with aripiprazole/haloperidol after prior treatment with risperidone.
Letmaier M; Painold A; Holl AK; Grohmann R; Vergin H
Int J Psychiatry Clin Pract; 2012 Jun; 16(2):153-6. PubMed ID: 22211772
[TBL] [Abstract][Full Text] [Related]
17. [The use of atypical antipsychotics in the long-term care of schizophrenia].
Limosin F
Encephale; 2006 Dec; 32 Pt 3():S1065-71. PubMed ID: 17356501
[No Abstract] [Full Text] [Related]
18. Effects of amisulpride and aripiprazole on progressive-ratio schedule performance: comparison with clozapine and haloperidol.
den Boon FS; Body S; Hampson CL; Bradshaw CM; Szabadi E; de Bruin N
J Psychopharmacol; 2012 Sep; 26(9):1231-43. PubMed ID: 21969105
[TBL] [Abstract][Full Text] [Related]
19. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial.
Barbui C; Accordini S; Nosè M; Stroup S; Purgato M; Girlanda F; Esposito E; Veronese A; Tansella M; Cipriani A;
J Clin Psychopharmacol; 2011 Jun; 31(3):266-73. PubMed ID: 21508849
[TBL] [Abstract][Full Text] [Related]
20. Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic.
Ramaekers JG; Louwerens JW; Muntjewerff ND; Milius H; de Bie A; Rosenzweig P; Patat A; O'Hanlon JF
J Clin Psychopharmacol; 1999 Jun; 19(3):209-21. PubMed ID: 10350027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
